Navigation Links
Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
Date:12/17/2007

t Baxter's Thrombin (Human)

Baxter's human thrombin is made from human plasma and has been a component in products used in the surgical setting for nearly 15 years.

As with all human plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses, cannot be totally eliminated.

About GELFOAM

GELFOAM is a sterile, pliable, surgical sponge prepared from specially treated, purified gelatin solution and capable of absorbing and holding within its meshes many times its weight in whole blood. It is used as a hemostatic device.

GELFOAM is a registered trademark of Pharmacia & Upjohn Company LLC.

About Baxter

Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

About Pfizer Inc

Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments, and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, nearly 90,000 colleagues in more than 150 countries work every day to help people s
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: ... develops and commercializes proprietary technologies and products for ... has received approval from the TSX Venture Exchange ... share purchase warrants ("the Warrants") of the Company, ... May 2013 private placement financing. Each ...
(Date:4/17/2015)... BellBrook Labs announced today that ... the powerful Orthogonal Pooled Screening (OPS) Platform developed ... the Lankenau Institute for Medical Research (LCGC) in ... improve successful drug discovery outcomes using far more ... libraries available nowhere else, coupled to a state-of-the-art ...
(Date:4/16/2015)... April 16, 2015 Capillus, LLC ... and physician network in Europe and Asia. The ... appointed Fernando Bermúdez, former Business Development Director of ... industry veteran, Mr. Bermúdez’s professional achievements include increasing ... Spain, while also penetrating the Portuguese marketplace with ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2
... Antidepressant Can Help Adults Living With ... Relief -(1), PRINCETON, N.J. and TOKYO, Nov. ... and Otsuka Pharmaceutical Co.,Ltd. announced today that the ... New Drug Application for ABILIFY(R),(aripiprazole) as adjunctive, or ...
... BB: CLBE), an emerging life sciences company ( http://www.CalbaTech.com ... stem cells for,possible future therapeutic uses and providing products ... to academic,institutions, said today in its 10Q filing with ... be profitable in 2007. The addition of sales ...
... will present at the Piper Jaffray 19th Annual Healthcare ... Pierre Hotel in New York. John L.,Bishop, Chief Executive ... Chief Financial Officer, will provide a corporate overview. ... be,accessed on Cepheid,s Web site at http://www.cepheid.com ...
Cached Biology Technology:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 2U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 4U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 5U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 6U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 7U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 8U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 9CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 2CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 3Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Wistar Institute have deciphered the structure of the active ... role in the development of nearly all human cancers. ... of new, broadly effective cancer drugs, as well as ... a decade to find drugs that shut down telomerasewidely ...
... have long known to be related to each other women ... Now, a master switch has been found in the brain of ... Biological Studies say it may work the same way in humans. ... Aug. 31 online edition of Nature Medicine , suggest that ...
... was reached by the Alliance for a Healthier Generation ... on "competitive foods" such as soft drinks at schools. ... the availability of soft drinks at school may not ... children. In a study of more than 4,000 ...
Cached Biology News:Landmark study opens door to new cancer, aging treatments 2Landmark study opens door to new cancer, aging treatments 3New master switch found in the brain that regulates appetite and reproduction 2New master switch found in the brain that regulates appetite and reproduction 3New master switch found in the brain that regulates appetite and reproduction 4
... Topo I, Wild Type ... Tris-HCl, 1 mM DTT, 200 µM EDTA, 20% ... topoisomerase I (Topo I) is a monomeric protein ... gene. It catalyzes the relaxation of both positive ...
RNase-Free DNase 50 l...
Request Info...
... is a DNA-dependent RNA polymerase which is ... It efficiently synthesizes in vitro transcripts from ... from a T7 promoter. Transcripts can ... in vitro translation, substrates in RNA processing ...
Biology Products: